Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Mereo BioPharma Group plc, a ... therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment ... Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. Incyte (NASDAQ:INCY – Get Free Report) and Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastat The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
Original title: “Head-To-Head Review: Incyte (NASDAQ:INCY) and Mereo BioPharma Group (NASDAQ:MREO) - American Market News”
This proposed rule would implement section 6219 (Adjustments to Medicare Part D Cost-Sharing Reductions for Low-Income Individuals), section 6220 (Requiring Enhanced and Accurate Lists of (REAL) Health Providers Act), and section 6224 (Modernizing and Ensuring Pharmacy Benefit Manager Accountability) of the Consolidated Appropriations Act, 2026.
Original title: “Medicare Program; Implementation of Sections 6219, 6220, and 6224 of the Consolidated Appropriations Act, 2026”
New study bolsters recommendations to base initial treatment on clinical response One long-term study reported in 2024 showed that outcomes from early TTT were still good as long as 20 years after starting therapy, although it involved participants in two separate Dutch trials that used different TTT strategies. The current study followed participants in a Norwegian trial called ARCTIC, whose initial results were reported in 2016. It enrolled 230 patients who were randomized to two similar TTT strategies: both had clinical remission as the target, but one also included completely negative ultrasound findings of inflammation at all joints tested. Moreover, the median change in modified van der Heijde-Sharp score for radiographic damage was just 2.0 points (IQR 0.5-4.5). With scores averaging 0.5 at baseline, and a maximum possible score of 448, the authors called this degree of progression "limited" in their report, appearing in Annals of the Rheumatic Diseases. These findings, the investigators wrote, "support current treatment recommendations for RA and offer reassurance to patients newly diagnosed with RA that clinical remission, preserved function, and favorable long-term survival are realistic long-term outcomes." This study examined 10-year outcomes among participants in a stringent treat-to-target trial, with data from 82% of survivors from the original enrollment. More than 80% were in clinical remission at year 10, with "limited" radiographic progression during follow-up. Most patients with rheumatoid arthritis (RA) whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. Those who had achieved clinical remission (DAS <1.6) at year 2 were significantly more likely to keep that status at year 10 (89.9%), compared with those with poorer short-term outcomes (73.1%, P=0.01). Other outcomes including the more conventional 28-joint DAS, ultrasound findings, ACR/EULAR 2.0 remission, and measures of systemic inflammation all showed significantly more disease activity at year 10, albeit still generally low, among those not reaching remission at year 2.
Original title: “Excellent 10-Year Outcomes After Early Treat-to-Target in Rheumatoid Arthritis | MedPage Today”
astrocytic expression of interferon induced myxovirus resistance protein a and protein kinase r in prion diseases distinct plaque associated myxovirus resistance protein a localization in gerstmann str ussler scheinker disease
Original title: “Astrocytic expression of interferon-induced myxovirus resistance protein A and protein kinase R in prion diseases: Distinct plaque-associated myxovirus resistance protein A localization in Gerstmann-Sträussler-Scheinker disease.”
advances and challenges in inner ear drug delivery limitations and therapeutic perspectives
Original title: “Advances and challenges in inner ear drug delivery: limitations and therapeutic perspectives.”
inflammatory breast cancer the evolution of diagnosis and modern clinical management
Original title: “Inflammatory Breast Cancer-The Evolution of Diagnosis and Modern Clinical Management.”
contrast enhanced ultrasound in the diagnosis of parotid gland castleman disease in a child
Original title: “Contrast-Enhanced Ultrasound in the Diagnosis of Parotid Gland Castleman Disease in a Child.”
venous wash out at contrast enhanced ultrasound for the identification of hematologic splenic lesions an exploratory real world substudy
Original title: “Venous wash-out at contrast-enhanced ultrasound for the identification of hematologic splenic lesions: an exploratory real-world substudy.”
identification and interfering factors of falsely elevated androgen levels in clinical laboratory testing in women
Original title: “[Identification and interfering factors of falsely elevated androgen levels in clinical laboratory testing in women].”
delayed diagnosis of familial glucocorticoid deficiency type 4 in a child with epilepsy a case report and literature review
Original title: “Delayed diagnosis of familial glucocorticoid deficiency type 4 in a child with epilepsy: a case report and literature review.”